Management of acquired haemophilia A in severe Covid‐19: Haemostatic bridging with emicizumab to keep the balance between bleeding and thrombosis

Acquired haemophilia A (AHA) is an autoimmune bleeding disorder caused by autoantibodies blocking coagulation factor VIII (FVIII). Haemostatic management of AHA and concomitant thrombotic risk is difficult. We cover the management of a 75‐year‐old male with severe Covid‐19, a prothrombotic disease,...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelbenegger, Georg, Traby, Ludwig, Rahimi, Nina, Knöbl, Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877795/
https://www.ncbi.nlm.nih.gov/pubmed/36369653
http://dx.doi.org/10.1111/bcp.15598

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9877795/
https://www.ncbi.nlm.nih.gov/pubmed/36369653
http://dx.doi.org/10.1111/bcp.15598

Ejemplares similares